IMGT (XKRX:456570) Debt-to-Revenue : 3.27 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

IMGT's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩69.79 Mil. IMGT's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩68.75 Mil. IMGT's annualized Revenue for the quarter that ended in Dec. 2023 was ₩42.40 Mil. IMGT's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 3.27.

IMGT Debt-to-Revenue Historical Data

The historical data trend for IMGT's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Debt-to-Revenue Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

259.68

2.24

3.27

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Debt-to-Revenue	N/A	259.68	2.24	3.27

Competitive Comparison of IMGT's Debt-to-Revenue

For the Biotechnology subindustry, IMGT's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMGT's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IMGT's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where IMGT's Debt-to-Revenue falls into.

IMGT Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

IMGT's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(69.791	+	68.753)	/	42.4
	=	3.27

IMGT's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(69.791	+	68.753)	/	42.4
	=	3.27

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (Dec. 2023) Revenue data.

IMGT Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of IMGT's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT (XKRX:456570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines